<?xml version="1.0" encoding="UTF-8"?>
<p id="p0030">Regulatory processes for the routine development of medicinal and medical device products were gradually standardized over the first 8 decades of the 20th century
 <xref rid="bib11" ref-type="bibr">
  <sup>11</sup>
 </xref> to meet the medical and scientific communities' expectations of the majority of products, although improvements in timeliness would have to await the enactment of user fees in the 1990s to address business expectations. The HIV epidemic that began in the early 1980s had laid bare weaknesses in the standardized routine model of drug development in responding to the urgent pressures of expedited development of new drugs and in facilitating the availability of promising drugs to large numbers of patients without alternatives during company preparation of NDAs and FDA reviews of applications. These experiences acute attention to the need for expedited development processes and Expanded Access approaches to medicinal products prior to FDA approval.
</p>
